Cancer |
Virus |
Participants |
Clinical outcomes |
Reference |
Melanoma |
T-VEC |
436 |
Improved longer-term efficacy and overall survival (mOS 23.3 months, ORR 31.5%, and CR 16.9%) |
[45] |
PVSRIPO |
12 |
OR: 33%, pCR in two patients, no progression in 50% in 18 months |
[47] |
Poxvirus |
1 |
Clinical regression of the lesion with grade ½ AEs |
[106] |
Pediatric DIPG |
DNX-2401 |
12 |
mOS 17,8 months, Reduction in tumor size in 75%, PR: 25%, SD: 67%, 2 patients achieved 3 years-survival. |
[49] |
GBM |
G47∆ |
19 |
mOS: 20.2 months, 1-year survival in 84.2%, PR: 1 patient, SD: 18 patients, |
[52] |
Reolysin |
15 |
mOS: 13.1 months, 2-year survival in 33%. |
[54] |
Pediatric MG, AA, and RE |
AdV-tk |
8 |
2-year survival: 37.5%, 2 patients > 36 months, AEs: Grade 1/2 |
[55] |
HNSCC |
GL-ONC1 |
19 |
PFS in 1st year: 74.7% and in 2nd year: 64.1% OS in 1st year: 84.6%, 2nd year: 69.2% |
[57] |
T-VEC |
36 |
ORR: 16.7%, six paitents had PR and 8 patients had SD. |
[58, 59] |
rAd-p53 |
102 |
Improved OS and disease-free survival rates |
[60] |
NSCLC |
TG4010 |
222 |
Improved PF survival among TG4010 compared to placebo, only 4% had grade 3/4 AEs . |
[62] |
MEM-288 |
11 |
No DLTs. SD: 2 patients and PD: 5 patients. |
[107] |
MPM |
HSV1716 |
12 |
SD: 50% |
[65] |
Esophageal cancer |
OBP-301 |
13 |
ORR: 91.7%, CR: 61.5%, PR: 13% |
[66] |
CRC |
Reolysin |
30 |
PR: 20%, SD: 73.3%, mOS: 25.1 months |
[67] |
OH2 |
54 (35 with CRC) |
SD: 13 patients, PR: 2 patients, Tumor with lymph node metastasis regression in 2 patients |
[69] |
LAPC |
HF10 |
9 |
PR: 33%, SD: 44%, mOS: 15.1 months |
[71] |
Ad5-DS |
9 |
SD: eight patients, PR: one patient, median PFS: 11.4 months. |
[73] |
Reolysin |
10 |
Disease control in 3 patients: 1 PR for 17.4 months, 2 SD for 9 and 4 months. Grade 1-2 AEs. |
[108] |
HCC |
AdV-tk |
77 |
Improved 5-year survival |
[76] |
JX-594 |
30 |
Improved OS with CR in one patient |
|
mBC |
AdV-tk |
28 |
Clinical benefit: 21.43%, PR: 1 patient, SD: 3 patients, CR: 2 patients (1 patient remains disease-free for 39 months). |
[79] |
T-VEC |
9 |
pCR: 55% with lymph node metastasis regression in 3 patients, |
[80] |
Reolysin |
74 |
Improved mOS: 17.4 months |
[109] |
PROC |
Olvi-Vec |
12 |
SD: 64%, Improved OS in 3 patients > 30 months, |
[83] |
enadenotucirev |
38 |
SD: 35%, reduction in tumor burden in 65% |
[84] |
CRPC |
GEN0101 |
9 |
SD: 67% and reduction of lymph node metastasis in 3 patients |
[90] |
AdV PSA/MUC1/brachyury |
18 |
SD: 5 patients, PR: 1 patient, Notable decline in PSA levels. |
[91] |
Bladder cancer |
CG0070 |
35 |
CR in 6, 12, and 18 months: 44%, 30%, and 23% respectively |
[94, 95] |
Nadofaragene firadenovec |
157 |
Improved 2-year survival rate |
[97] |
RCC |
Pexa-Vec |
16 |
Tumor reduction and overall disease control 75% |
[98] |
CBCL |
TG1042 |
11 |
CR: 63.6% and PR: 36.4% |
[103] |
CLL |
Ad-ISF35 |
15 |
PR: 20%, SD: 46.7%, with reduction in lymphadenopathy and splenomegaly |
[105] |